Repositioning of the global epicentre of non-optimal cholesterol

被引:206
作者
Taddei, Cristina [1 ]
Zhou, Bin [1 ]
Bixby, Honor [1 ]
Carrillo-Larco, Rodrigo M. [1 ]
Danaei, Goodarz [2 ]
Jackson, Rod T. [3 ]
Farzadfar, Farshad [4 ]
Sophiea, Marisa K. [1 ]
Di Cesare, Mariachiara [5 ]
Iurilli, Maria Laura Caminia [1 ]
Martinez, Andrea Rodriguez [1 ]
Asghari, Golaleh [66 ]
Dhana, Klodian [7 ]
Gulayin, Pablo [8 ]
Kakarmath, Sujay [9 ]
Santero, Marilina [8 ]
Voortman, Trudy [10 ]
Riley, Leanne M. [11 ]
Cowan, Melanie J. [11 ]
Savin, Stefan [11 ]
Bennett, James E. [1 ]
Stevens, Gretchen A. [1 ]
Paciorek, Christopher J. [12 ]
Aekplakorn, Wichai [13 ]
Cifkova, Renata [14 ,15 ]
Giampaoli, Simona [16 ]
Kengne, Andre Pascal [17 ]
Khang, Young-Ho [18 ]
Kuulasmaa, Kari [19 ]
Laxmaiah, Avula [20 ]
Margozzini, Paula [21 ]
Mathur, Prashant [22 ]
Nordestgaard, Borge G. [23 ]
Zhao, Dong [24 ]
Aadahl, Mette [25 ]
Abarca-Gomez, Leandra [26 ]
Rahim, Hanan Abdul [27 ]
Abu-Rmeileh, Niveen M. [28 ]
Acosta-Cazares, Benjamin [29 ]
Adams, Robert J. [30 ]
Agdeppa, Imelda A. [31 ]
Aghazadeh-Attari, Javad [32 ]
Aguilar-Salinas, Carlos A. [33 ]
Agyemang, Charles [34 ]
Ahluwalia, Tarunveer S. [35 ]
Ahmad, Noor Ani [36 ]
Ahmadi, Ali [37 ]
Ahmadi, Naser [4 ]
Ahmed, Soheir H. [38 ]
Ahrens, Wolfgang [39 ]
机构
[1] Imperial Coll London, London, England
[2] Harvard TH Chan Sch Publ Hlth, Boston, MA USA
[3] Univ Auckland, Auckland, New Zealand
[4] Univ Tehran Med Sci, Tehran, Iran
[5] Middlesex Univ, London, England
[6] Shahid Beheshti Univ Med Sci, Tehran, Iran
[7] Rush Univ, Med Ctr, Chicago, IL 60612 USA
[8] Inst Clin Effectiveness & Hlth Policy, Buenos Aires, DF, Argentina
[9] Harvard Med Sch, Boston, MA 02115 USA
[10] Erasmus MC, Rotterdam, Netherlands
[11] WHO, Geneva, Switzerland
[12] Univ Calif Berkeley, Berkeley, CA 94720 USA
[13] Mahidol Univ, Salaya, Nakhon Pathom, Thailand
[14] Charles Univ Prague, Prague, Czech Republic
[15] Thomayer Hosp, Prague, Czech Republic
[16] Ist Super Sanita, Rome, Italy
[17] South African Med Res Council, Cape Town, South Africa
[18] Seoul Natl Univ, Seoul, South Korea
[19] Finnish Inst Hlth & Welf, Helsinki, Finland
[20] ICMR Natl Inst Nutr, Hyderabad, India
[21] Pontificia Univ Catolica Chile, Santiago, Chile
[22] ICMR Natl Ctr Dis Informat & Res, Bengaluru, India
[23] Copenhagen Univ Hosp, Copenhagen, Denmark
[24] Capital Med Univ, Beijing An Zhen Hosp, Beijing, Peoples R China
[25] Bispebjerg & Frederiksberg Hosp, Copenhagen, Denmark
[26] Caja Costarricense Seguro Social, San Jose, Costa Rica
[27] Qatar Univ, Doha, Qatar
[28] Birzeit Univ, Birzeit, Palestine
[29] Inst Mexicano Seguro Social, Mexico City, DF, Mexico
[30] Flinders Univ S Australia, Adelaide, SA, Australia
[31] Food & Nutr Res Inst, Taguig, Philippines
[32] Urmia Univ Med Sci, Orumiyeh, Iran
[33] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Mexico City, DF, Mexico
[34] Univ Amsterdam, Amsterdam, Netherlands
[35] Steno Diabet Ctr Copenhagen, Gentofte, Denmark
[36] Minist Hlth Malaysia, Kuala Lumpur, Malaysia
[37] Shahrekord Univ Med Sci, Shahrekord, Iran
[38] Univ Oslo, Oslo, Norway
[39] Univ Bremen, Bremen, Germany
[40] Natl Ctr Diabet Endocrinol & Genet, Amman, Jordan
[41] Dasman Diabet Inst, Kuwait, Kuwait
[42] Aldara Hosp & Med Ctr, Riyadh, Saudi Arabia
[43] King Abdullah Int Med Res Ctr, Riyadh, Saudi Arabia
[44] Luxembourg Inst Hlth, Strassen, Luxembourg
[45] WHO Reg Off Eastern Mediterranean, Cairo, Egypt
[46] Bombay Hosp & Med Res Ctr, Mumbai, Maharashtra, India
[47] Univ Lille, Lille, France
[48] Lille Univ Hosp, Lille, France
[49] Western Norway Univ Appl Sci, Sogndal, Norway
[50] Norwegian Sch Sport Sci, Oslo, Norway
基金
英国惠康基金; 英国经济与社会研究理事会; 英国医学研究理事会;
关键词
DENSITY-LIPOPROTEIN CHOLESTEROL; CARDIOVASCULAR RISK-FACTORS; SERUM-CHOLESTEROL; ATHEROSCLEROSIS SOCIETY; 20-YEAR TRENDS; BLOOD-PRESSURE; MEDICATION USE; HEART-DISEASE; LIPIDS; POPULATION;
D O I
10.1038/s41586-020-2338-1
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
High blood cholesterol is typically considered a feature of wealthy western countries(1,2). However, dietary and behavioural determinants of blood cholesterol are changing rapidly throughout the world(3) and countries are using lipid-lowering medications at varying rates. These changes can have distinct effects on the levels of high-density lipoprotein (HDL) cholesterol and non-HDL cholesterol, which have different effects on human health(4,5). However, the trends of HDL and non-HDL cholesterol levels over time have not been previously reported in a global analysis. Here we pooled 1,127 population-based studies that measured blood lipids in 102.6 million individuals aged 18 years and older to estimate trends from 1980 to 2018 in mean total, non-HDL and HDL cholesterol levels for 200 countries. Globally, there was little change in total or non-HDL cholesterol from 1980 to 2018. This was a net effect of increases in low- and middle-income countries, especially in east and southeast Asia, and decreases in high-income western countries, especially those in northwestern Europe, and in central and eastern Europe. As a result, countries with the highest level of non-HDL cholesterol-which is a marker of cardiovascular riskchanged from those in western Europe such as Belgium, Finland, Greenland, Iceland, Norway, Sweden, Switzerland and Malta in 1980 to those in Asia and the Pacific, such as Tokelau, Malaysia, The Philippines and Thailand. In 2017, high non-HDL cholesterol was responsible for an estimated 3.9 million (95% credible interval 3.7 million-4.2 million) worldwide deaths, half of which occurred in east, southeast and south Asia. The global repositioning of lipid-related risk, with non-optimal cholesterol shifting from a distinct feature of high-income countries in northwestern Europe, north America and Australasia to one that affects countries in east and southeast Asia and Oceania should motivate the use of population-based policies and personal interventions to improve nutrition and enhance access to treatment throughout the world.
引用
收藏
页码:73 / +
页数:22
相关论文
共 77 条
[1]  
[Anonymous], 1997, PREV MED
[2]  
[Anonymous], 2005, BRIT J CLIN PHARMACO, DOI DOI 10.1111/J.1365-2125.2005.02478.X
[3]  
[Anonymous], 2016, EUR HEART J, DOI DOI 10.1093/EURHEARTJ/EHW052
[4]  
[Anonymous], 2006, ATHEROSCLEROSIS SUPP, DOI DOI 10.1016/J.ATHEROSCLEROSISSUP.2006.04.019
[5]  
[Anonymous], 2016, BMC PUBLIC HLTH, DOI DOI 10.1186/S12889-016-2826-2
[6]  
[Anonymous], 2019, LANCET, DOI DOI 10.1016/S0140-6736(18)32744-2
[7]  
[Anonymous], 2018, INT J CARDIOL, DOI DOI 10.1016/J.IJCARD.2017.12.069
[8]  
[Anonymous], 2016, EUR HEART J, DOI DOI 10.1093/EURHEARTJ/EHW152
[9]  
[Anonymous], 2005, JAMA J AM MED ASSOC
[10]  
[Anonymous], 2016, JAMA J AM MED ASSOC, DOI DOI 10.1001/JAMA.2016.4666